Posted by Michael Wonder on 15 Jun 2021
Cerevel Therapeutics announces fast track designation granted by the U.S. FDA to CVL-871 for the treatment of dementia related apathy
15 June 2021 - Cerevel Therapeutics announced that the U.S. FDA has granted fast track designation to CVL-871, a D1/D5 partial agonist in development for the treatment of dementia-related apathy.
CVL-871 is a selective dopamine D1/D5 partial agonist specifically designed to achieve a modest level of partial agonism that may be useful in modulating the complex neural networks that govern apathy-related behaviours in neurodegenerative diseases.
